IP Library Granted Patent US 8,617,521
Granted Patent B2
US 8,617,521 · App. 13/195,570 · Granted Dec 31, 2013

Phage antibodies to radiation-inducible neoantigens

Inventors: Dennis E. Hallahan (St. Louis, MO); Raymond Mernaugh (St. Louis, MO)
Assignee: Vanderbilt University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,617,521
App. No.
13/195,570
Granted
Dec 31, 2013
Kind
B2
Abstract

A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor.

Claims (8)

1. A method of detecting a tumor in a mammalian subject, the method comprising: (a) exposing a suspected tumor to ionizing radiation; (b) administering to the subject an immunoconjugate composition comprising a single chain fragment variable (scFv) antibody that binds to a radiation-inducible neoantigen derived from tumor vascular endothelium selected from the group consisting of P-selectin, E-selectin, endoglin, α 2b β 3 integrin and α v β 3 integrin, or a Fab fragment thereof, conjugated to a detectable label; and (c) detecting the detectable label, whereby a tumor is detected.

2. The method of claim 1 , wherein the immunoconjugate is polyvalent.

3. The method of claim 1 , wherein the single chain fragment variable (scFv) antibody or Fab antibody is humanized.

4. The method of claim 1 , wherein the immunoconjugate is administered to the subject in a pharmaceutically acceptable carrier.

5. The method of claim 1 , further comprising a detectable label.

6. The method of claim 1 , wherein the detectable label comprises a label that can be detected using magnetic resonance imaging, scintigraphic imaging, ultrasound, or fluorescence.

7. The method of claim 6 , wherein the label that can be detected using scintigraphic imaging comprises a radionuclide label.

8. The method of claim 1 , wherein the radionuclide label comprises 131 I or 99 mTc.

Assignments (1)
CONFIRMATORY LICENSE Recorded Apr 3, 2017
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042134/0304 →
Continuity (5)
Division 11953780 · Dec 10, 2007
Division 10689006 · Oct 20, 2003
Continuation In Part 10259087 · Sep 27, 2002
Continuation In Part 09914605 · Nov 9, 2001
Related Publication 20120041303A1 · Feb 16, 2012